4-Phenylcoumarins as HIV transcription inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 20, 2005, Pages 4447-4450

  Bedoya, Luis M ^a   Beltrán, Manuela ^a   Sancho, Rocío ^b   Olmedo, Dionisio A ^c,d   Sánchez Palomino, Sonsoles ^a   Del Olmo, Esther ^d   López Pérez, José L ^d   Muñoz, Eduardo ^b   San Feliciano, Arturo ^d   Alcamí, José ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSITY OF CÓRDOBA   (Spain)

^c UNIVERSIDAD DE PANAMÁ   (Panama)

^d UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Coumarins; HIV; HIV transcription; Natural products

Indexed keywords

ANTIVIRUS AGENT; COUMARIN DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; PROTEIN INHIBITOR; TRANSACTIVATOR PROTEIN; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG ISOLATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; MARILA PLURICOSTATA; MEDICINAL PLANT; MOLECULAR CLONING; PROTEIN FUNCTION; REPORTER GENE; VIRUS TRANSCRIPTION;

MARILA;

EID: 24344452968     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.07.041     Document Type: Article

References (21)

1. A.B. Rabson, and H.C. Lin Adv. Pharmacol. 48 2000 161
2. A. Gatignol, M. Duarte, L. Daviet, Y.N. Chang, and K.T. Jeang Gene Expr. 5 1996 217
3. B.K. Chen, M.B. Feinberg, and D. Baltimore J. Virol. 71 1997 5495
4. W.C. Greene N. Engl. J. Med. 324 1991 308
5. J. Alcami, T. Lain de Lera, L. Folgueira, M.A. Pedraza, J.M. Jacque, F. Bachelerie, A.R. Noriega, R.T. Hay, D. Harrich, and R.B. Gaynor EMBO J. 14 1995 1552
6. M. Stevenson Nat. Med. 9 2003 163
7. P.G. Yeni, S.M. Hammer, C.C. Carpenter, D.A. Cooper, M.A. Fischl, J.M. Gatell, B.G. Gazzard, M.S. Hirsch, D.M. Jacobsen, D.A. Katzenstein, J.S. Montaner, D.D. Richman, M.S. Saag, M. Schechter, R.T. Schooley, M.A. Thompson, S. Vella, and P.A. Volberding JAMA 288 2002 222
8. M. Karin, Y. Yamamoto, and Q.M. Wang Nat. Rev. Drug Discov. 3 2004 17
9. A.J. Vlietinck, T. De Bruyne, S. Apers, and L.A. Pieters Planta Med. 64 1998 97
10. D. Yu, M. Suzuki, L. Xie, S.L. Morris-Natschke, and K.-H. Lee Med. Res. Rev. 23 2003 322
11. F. Uchiumi, T. Hatano, H. Ito, T. Yoshida, and S.I. Tanuma Antiviral Res. 58 2003 89
12. E. De Clercq J. Clin. Virol. 30 2004 115
13. Z.-Q. Xu, W.W. Barrow, W.J. Suling, L. Westbrook, E. Barrow, Y.-M. Lin, and M.T. Flavin Biorg. Med. Chem. 12 2004 1199
14. J.L. López-Pérez, D.A. Olmedo, E. del Olmo, Y. Vásquez, P.N. Solís, M.P. Gupta, and A. San Feliciano J. Nat. Prod. 68 2005 369
15. I.N. Gougerot-Pocidalo, M.A. Aillet, and J.L. Virelizier J. Immunol. 149 1992 3386
16. The HeLa-Tat-Luc system contains the same reporter plasmid as 5.1 cells and the Tat gene regulated by the CMV promoter. Therefore, the HIV-1 LTR is highly activated in this cell line as a consequence of high levels of intracellular Tat protein.
17. R. Sancho, M. Medarde, S. Sanchez-Palomino, B.M. Madrigal, J. Alcami, E. Muñoz, and A. San Feliciano Bioorg. Med. Chem. Lett. 14 2004 4483
18. R. Sancho, N. Márquez, M. Gómez-Gonzalo, M. Calzado, G. Vetón, M. Coiras, J. Alcamí, M. López-Cabreras, G. Appendino, and E. Muñoz J. Biol. Chem. 279 2004 37349
19. Propidium iodide cell viability: virus infectious and toxicity assays were performed at the same time. Briefly, MT-2 cells were seeded in 24-well microtitre culture plates (5 × 105 per well) and samples were added to obtain a final concentration equal to that used in the recombinant virus assays. After 48 h treatment, cells were collected and analysed by flow cytometry after propidium iodide staining. We determined here the percentage of cells not affected by the sample.
20. N. Marquez, R. Sancho, L.M. Bedoya, J. Alcami, J.L. Lopez-Perez, A.S. Feliciano, B.L. Fiebich, and E. Munoz Antiviral Res. 66 2005 137
21. B. Furia, L. Deng, K. Wu, S. Baylor, K. Kehn, H. Li, R. Donnelly, T. Coleman, and F. Kashanchi J. Biol. Chem. 277 2002 4973